What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells ...

Merck ($MRK) stock rose about 4% on Monday, as of writing, after top Wells Fargo analyst Mohit Bansal upgraded his rating for the pharma company ...

Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90. The ...

Investing.com -- Merck shares received an upgrade at Wells Fargo, with analyst Mohit Bansa lifting the stock to Overweight ...

Merck (MRK) stock in focus as the company urges shareholders to reject a mini-tender offer which stands at a 25% discount to ...

Merck has bullish valuation metrics and is trading above its 30-week EMA with bullish long-term momentum. Learn why MRK stock ...

Merck stock has reached a notable milestone, hitting a 52-week high of 105.08 USD. This peak marks a significant point for the pharmaceutical giant, reflecting investor confidence and market momentum.

Merck (MRK)’s stock surged by 41%, driven not significantly by revenue but rather by increased profits and heightened ...

Over the past two years, Merck ( MRK 0.19%) has faced several challenges, resulting in a decline in the company's share price ...

The article " Merck Writes a $9.2 Billion Check for a Flu Drug That Could Change Everything " first appeared on MarketBeat.

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...